Immunocore Holdings plc (NASDAQ:IMCR – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2023 EPS estimates for Immunocore in a report issued on Thursday, November 2nd. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will earn ($1.74) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($1.34) per share. Cantor Fitzgerald also issued estimates for Immunocore’s FY2024 earnings at ($2.28) EPS.
Immunocore (NASDAQ:IMCR – Get Free Report) last posted its earnings results on Thursday, August 10th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.03. The firm had revenue of $60.70 million during the quarter, compared to analysts’ expectations of $59.39 million. Immunocore had a negative net margin of 27.72% and a negative return on equity of 17.97%.
Immunocore Stock Up 5.6 %
IMCR stock opened at $49.15 on Monday. The stock has a market capitalization of $2.41 billion, a P/E ratio of -38.10 and a beta of 0.75. The company has a current ratio of 4.28, a quick ratio of 4.26 and a debt-to-equity ratio of 0.23. Immunocore has a 12 month low of $42.21 and a 12 month high of $69.06. The firm has a 50-day moving average price of $50.60 and a 200-day moving average price of $56.69.
Institutional Trading of Immunocore
Several large investors have recently modified their holdings of IMCR. Virtu Financial LLC bought a new position in shares of Immunocore in the 1st quarter worth $496,000. Oppenheimer Asset Management Inc. bought a new position in shares of Immunocore in the 2nd quarter worth $355,000. Wellington Management Group LLP lifted its holdings in shares of Immunocore by 56.8% in the 1st quarter. Wellington Management Group LLP now owns 3,375,309 shares of the company’s stock worth $166,875,000 after purchasing an additional 1,222,343 shares in the last quarter. Exchange Traded Concepts LLC bought a new position in shares of Immunocore in the 2nd quarter worth $148,000. Finally, Brown Advisory Inc. bought a new position in shares of Immunocore in the 2nd quarter worth $240,000. Institutional investors and hedge funds own 73.45% of the company’s stock.
Immunocore Company Profile
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers.
- Five stocks we like better than Immunocore
- How to Invest in Renewable Energy
- MarketBeat Week in Review – 10/30 – 11/3
- Following Congress Stock Trades
- Shocking uranium play that hedge funds kept hidden
- How to Invest in Cybersecurity
- Dependable dividends: Why utility stocks are on fire
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.